Stay updated on APX005M + Pembrolizumab in Metastatic Melanoma Clinical Trial
Sign up to get notified when there's something new on the APX005M + Pembrolizumab in Metastatic Melanoma Clinical Trial page.

Latest updates to the APX005M + Pembrolizumab in Metastatic Melanoma Clinical Trial page
- CheckyesterdayChange DetectedA new history version (version 39) was added for NCT02706353 on 2025-10-08, indicating ongoing Quality Control Review and a results return date of 2025-10-23.SummaryDifference2%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check23 days agoChange Detected- Added a government-operating-status notice and a link to official sources, indicating the page may have dynamic status information. - Updated version from v3.1.0 to v3.2.0, signaling a new release.SummaryDifference9%

- Check30 days agoChange DetectedVersion update: from v3.0.2 to v3.1.0. This is a metadata revision with no substantive content changes.SummaryDifference0.2%

- Check44 days agoChange DetectedPage revision updated from v3.0.1 to v3.0.2; the Back to Top element was removed with no substantive content changes detected.SummaryDifference0.6%

- Check51 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes in core content or other important factors.SummaryDifference0.6%

- Check58 days agoChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location details, while removing specific state, country, and city information. This suggests a shift towards a more generalized presentation of location data.SummaryDifference47%

Stay in the know with updates to APX005M + Pembrolizumab in Metastatic Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the APX005M + Pembrolizumab in Metastatic Melanoma Clinical Trial page.